JRC Publications Repository

JRC Publications Repository >

Browsing by Author MORGENSTERN Alfred

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 40 to 59 of 136
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2008Development and Evaluation of Peptidic Ligands Targeting Tumor-associated Urokinase Plasminogen Activator Receptor (uPAR) for Use in Alpha-emitter Therapy of Disseminated Ovarian CancerKNOER S.; SATO S.; HUBER T.; MORGENSTERN ALFRED; BRUCHERTSEIFER FRANK; SCHMITT M.; KESSLER H.; SENEKOWITSCH-SCHMIDTKE R.; MAGDOLEN V.; SEIDL C.Articles in Journals
2013Development of a high-activity 225Ac/213Bi radionuclide generator for synthesis of clinical doses of 213Bi-labelled biomoleculesBRUCHERTSEIFER Frank; APOSTOLIDIS Christos; MIRZADEH Saed; BOLL Rose; MURPHY Karen; MORGENSTERN AlfredContributions to Conferences
2013Die Alpha-Emitter Radioimmuntherapie des multiplen Myeloms mit 213Bi-CHX-A“-DTPA-anti-CD38 Immunkonjugaten zeigt eine hohe Effizienz im präklinischen Xenograft-ModellTEILUF K; SEIDL C.; BLECHERT B.; GÄRTNER Florian; GILBERTZ K.-P.; FERNANDEZ V; BASSERMANN F; ENDELL J; BOXHAMMER R; AICHLER M, et alContributions to Conferences
2012Die intravesikale Radioimmuntherapie mit Bi-213-anti-EGFR Immunkonjugaten verursacht keine Schäden am UrothelMÜLLER Felix; SEIDL C.; WEIRICH G; RÖTZER S; FAZEL J; FRANK Annette; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2013DNA double strand break assessment as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor radiotherapyGRAF Franziska; FAHRER Jörg; MAUS Stephan; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; VENKATACHALAM S.; FOTTNER C.; WEBER Matthias M.; HUELSENBECK Johannes; SCHRECKENBERGER M, et alContributions to Conferences
2013DNA double strand break assessment by yH2AX-foci quantification after alpha-particle emitter Ac-225 and electron emitter Lu-177 somatostatin receptor targeted radiotherapy correlates with cell death and apoptosis in vitroGRAF Franziska; FAHRER Jörg; MAUS Stephan; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; VENKATACHALAM S.; FOTTNER C.; WEBER M.m.; HUELSENBECK Johannes; SCHRECKENBERGER M, et alContributions to Conferences
2014DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapyGRAF Franziska; FAHRER Jörg; MAUS Stephan; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; VENKATACHALAM S.; FOTTNER C.; WEBER M.m.; HUELSENBECK Johannes; SCHRECKENBERGER M, et alArticles in Journals
2012DTPA complexation of bismuth in human blood serumMONTAVON Gilles; LE DU Alicia; CHAMPION J; RABUNG T.; MORGENSTERN AlfredArticles in Journals
2012Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrestVALLON M.; SEIDL C.; BLECHERT B.; LI Zhoulei; GILBERTZ K.-P.; BAUMGART Anja; AICHLER M; FEUCHTINGER A; GAERTNER F. C.; BRUCHERTSEIFER Frank, et alArticles in Journals
2009Evidence of Extranuclear Cell Sensitivity to Alpha-particle Radiation Using a Microdosimetric Model - I - Presentation and Validation of a Microdosimetric ModelCHOUIN N; BERNARDEAU K; DAVODEAU F; CHÉREL M; FAIVRE-CHAUVET A; BOURGEOIS M; APOSTOLIDIS Christos; MORGENSTERN Alfred; LISBONA A; BARDIÈS MArticles in Journals
2009Evidence of Extranuclear Cell Sensitivity to Alpha-Particle Radiation Using a Microdosimetric Model - II - Application of the Microdosimetric Model to Experimental ResultsCHOUIN N; BERNARDEAU K; BARDIÈS M; FAIVRE-CHAUVET A; BOURGEOIS M; APOSTOLIDIS Christos; MORGENSTERN Alfred; LISBONA A; CHÉREL M; DAVODEAU F.Articles in Journals
2013Exploring the solution behavior of f-element coordination compounds: a case study on some trivalent rare earth and plutonium complexesLÖBLE Matthias; ONA-BURGOS Pascual; FERNANDEZ Ignacio; APOSTOLIDIS Christos; MORGENSTERN Alfred; WALTER Olaf; BRUCHERTSEIFER Frank; KADEN Peter; VITOVA T.; ROTHE J., et alArticles in Journals
2012Feasibility of 99Mo production by proton-induced fission of 232ThABBAS Kamel; HOLZWARTH Uwe; SIMONELLI Federica; KOZEMPEL JAN; CYDZIK Izabela; BULGHERONI A.; COTOGNO Giulio; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; MORGENSTERN AlfredArticles in Journals
2010A feasibility study of a new method for production of U-230/TH-226 fro alpha-immunotherapy applicationsABBAS Kamel; SIMONELLI Federica; CYDZIK Izabela; KOZEMPEL JAN; APOSTOLIDIS Christos; ZIELINSKA Barbara; BRUCHERTSEIFER Frank; MORGENSTERN AlfredContributions to Conferences
2013Feasibility study of direct cyclotron production of 227-ThKOZEMPEL J.; VLK M.; MICOLOVA P.; LEBEDA O.; MOSA M.; MORGENSTERN AlfredContributions to Conferences
2005Fractionated Locoregional Low-Dose Radioimmunotherapy Improves Survival in a Mouse Model of Diffuse Type Gastric Cancer Using A 213BI-conjugated Monoclonal AntibodyBLOECHEL S.; BECK R.; SEIDL C.; MORGENSTERN ALFRED; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2013Functionalized NaA nanozeolites as carriers for alpha emitting radionuclides.PIOTROWSKA A; LESZCZUK Edyta; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; BILEWICZ AleksanderContributions to Conferences
2013Functionalized NaA Nanozeolites Labeled with 224,225Ra for Targeted Alpha TherapyAGATA Piotrowska; EDYTA Leszczuk; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; BILEWICZ AleksanderArticles in Journals
2007Gemcitabine Radiosensitizes Multiple Myeloma Cells to Low LET, but not High LET, IrradiationSUPIOT S.; THILLAYS F.; RIO E.; GOUARD S.; MORGENSTERN ALFRED; BRUCHERTSEIFER FRANK; MAHE M. A.; CHATAL J. F.; DAVODEAU F.; CHEREL M.Articles in Journals
2013Half-lives of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay seriesSULIMAN GABRIEL; POMME Stefaan; MAROULI Maria; VAN AMMEL Raf; STROH HEIKO; JOBBAGY Viktor; PAEPEN Jan; DIRICAN A.; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos, et alArticles in Journals
Showing results 40 to 59 of 136

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top